Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01953354 · ClinicalTrials.gov registry record · Phase 2

Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis

A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Terminated
Registry status
Phase 2
Development phase
16
Enrollment target

NCT01953354 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01953354, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

TERMINATED
Registry status
Phase 2
Development phase
16 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of trichuris suis ova (TSO) in ulcerative colitis (UC). We will look at how TSO affects the body's immune response and if there are related changes in participants' UC.

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL Trichuris suis ova (TSO)

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2013-11
Est. Completion 2015-11
Phase Phase 2

What the Registry Record Tells You About NCT01953354

The ClinicalTrials.gov registry entry for NCT01953354 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01953354 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01953354 about?

NCT01953354 is a clinical study titled "Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis". The purpose of this study is to evaluate the safety and effectiveness of trichuris suis ova (TSO) in ulcerative colitis (UC). We will look at how TSO affects the body's immune response and if there are related changes in participants' UC.

What is the current status of trial NCT01953354?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2013-11. Estimated completion is 2015-11.

What interventions are being tested in trial NCT01953354?

The interventions under investigation include: Placebo (BIOLOGICAL), Trichuris suis ova (TSO) (BIOLOGICAL).

Who is sponsoring clinical trial NCT01953354?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.